Alkeon Capital Management
RLMD icon

Alkeon Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Alkeon Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100,000
Closed -$2.62M – 171
2021
Q3 		$2.62M Buy
100,000
+50,000
+100% +$1.34M ﹤0.01% 173
2021
Q2 		$1.6M Hold
50,000
– – ﹤0.01% 175
2021
Q1 		$1.76M Hold
50,000
– – ﹤0.01% 170
2020
Q4 		$1.6M Buy
+50,000
New +$1.72M ﹤0.01% 160

Other funds holding RLMD

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Alkeon Capital Management's RLMD Position: Q4 2021 in Review

Alkeon Capital Management sold out of Relmada Therapeutics (RLMD) in Q4 2021, closing a stake of 100,000 shares — an estimated $2.62M sold.

Alkeon Capital Management first reported a position in RLMD in Q4 2020 and held it in 4 quarters. The position peaked at $2.62M in Q3 2021. 97 funds tracked by Wall St. Rank hold RLMD as of Q4 2021.

  • Alkeon Capital Management reported no remaining Relmada Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Alkeon Capital Management sold 100,000 Relmada Therapeutics shares in Q4 2021, an estimated $2.62M.
  • Alkeon Capital Management first reported a position in Relmada Therapeutics in Q4 2020 and held it in 4 quarters.
  • Alkeon Capital Management's Relmada Therapeutics position peaked at $2.62M in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2021.

Based on Alkeon Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.